Armata Pharma surges on positive data for drug-resistant bacteria treatment

Armata Pharmaceuticals

28/05/2019 14:34

** Drug developer's shares  ARMP.A  surge 21% to $3.80
premarket 
    ** Announces publication of a case study involving a cystic
fibrosis patient who was successfully treated for a
multidrug-resistant Pseudomonas aeruginosa infection with co's
drug, AP-PA01  urn:newsml:reuters.com:*:nPnddG0Ya
    ** Pseudomonas aeruginosa is a common bacteria that can
cause infections in patients who have been hospitalized longer
than 1 week  
    ** The results were published in a peer-reviewed journal
    ** ARMP shares among top percentage gainers across U.S.
exchanges 
    ** As of Friday's close, ARMP shares have gained 9% this
year 

 (Reporting by Shreyashi Sanyal in Bengaluru)
 ((RM: Shreyashi.Sanyal.thomsonreuters.com@reuters.net))